Ophthalmology

• 

  People

  • Administrative Positions

    • Arshavsky, Vadim Y, Scientific Director, Ophthalmology
    • Arshavsky, Vadim Y, Co Vice-Chair of Basic Science Research
    • Buckley, Edward George, Chair, Department of Ophthalmology
    • Cousins, Scott William, Vice-Chair, Strategic Planning, Department of Ophthalmology
    • Freedman, Sharon Fridovich, Chief, Pediatric Ophthalmology
    • Medeiros, Felipe, Vice Chair, Technology
    • Postel, Eric Attila, Vice Chair, Clinical Affairs
    • Stamer, W Daniel, Co Vice-Chair of Basic Science Research
    • Toth, Cynthia Ann, Vice-Chair of Clinical Research
    • Whitaker, Diane Beasley, Chief, Vision Rehabilitation and Performance

  • Professorships

    • Buckley, Edward George, James Pitzer Gills, III, M.D. and Joy Gills Distinguished Professor of Ophthalmology in the School of Medicine
    • Hatchell, Diane L., Joseph A. C. Wadsworth Distinguished Research Professor Emeritus of Ophthalmology

  • Primary Appointments

    • Antoszyk, Andrew N., Assistant Consulting Professor of Ophthalmology
    • Beardsley, Thomas L., Consulting Associate in the Department of Ophthalmology
    • Berry, David Pinckney, Assistant Consulting Professor of Ophthalmology
    • Boisvert, Chantal Josee, Associate Professor of Ophthalmology
    • Bourgeois, John E., Assistant Consulting Professor of Ophthalmology
    • Browning, David Judson, Assistant Consulting Professor of Ophthalmology
    • Buckley, Edward George, Professor of Ophthalmology
    • Cheung, Nathan, Assistant Professor of Ophthalmology
    • Chou, Famin, Assistant Consulting Professor in the Department of Ophthalmology
    • Chowdhary, Geeta, Clinical Associate in the Department of Ophthalmology
    • Costello III, Martin Joseph, Adjunct Associate Professor in Ophthalmology
    • Crandall, James David, Assistant Consulting Professor in the Department of Ophthalmology
    • Devetski, Thomas Scott, Assistant Professor of Ophthalmology
    • Dolan, Hillary, Clinical Associate in the Department of Ophthalmology
    • Duff, Sarah Madison, Clinical Associate in the Department of Ophthalmology
    • Dunning, Madison Ivey, Medical Instructor in the Department of Ophthalmology
    • Eaton, Alexander Mellon, Consulting Associate in the Department of Ophthalmology
    • Enyedi, Laura Barlow, Professor of Ophthalmology
    • Firozvi, Asra Shabana, Clinical Associate in the Department of Ophthalmology
    • Foster, J. Thomas, Consulting Associate in the Department of Ophthalmology
    • Freedman, Sharon Fridovich, Professor of Ophthalmology
    • Gills, James P, Consulting Professor in the Department of Ophthalmology
    • Glaser, Tanya, Assistant Professor of Ophthalmology
    • Goldstein, Jeffrey Brian, Assistant Consulting Professor of Ophthalmology
    • Grace, Sara Fransen, Clinical Associate in the Department of Ophthalmology
    • Greenman, Herbert Emanuel, Assistant Consulting Professor of Ophthalmology
    • Halabis, Joseph Allen, Assistant Consulting Professor in Ophthalmology
    • Harris, William R., Consulting Associate in the Department of Ophthalmology
    • Hatchell, Diane L., Professor Emeritus of Ophthalmology
    • Horne, Anupama Betkerur, Assistant Professor of Ophthalmology
    • Isbey III, Edward Kenneth, Assistant Consulting Professor of Ophthalmology
    • Isbey Jr., Edward K., Consulting Professor of Ophthalmology
    • James, Charlene Lillian, Assistant Professor of Ophthalmology
    • Joslyn, Ann Katheryn, Consulting Associate in the Department of Ophthalmology
    • Lefler, W. Hampton, Consulting Associate in the Department of Ophthalmology
    • Maddala, Rupalatha, Assistant Professor of Ophthalmology
    • McKinley, Philip Howard, Assistant Professor Emeritus of Ophthalmology
    • McLean Jr., Walter Copley, Assistant Consulting Professor of Ophthalmology
    • Ouano, Dean Palanca, Consulting Associate in the Department of Ophthalmology
    • Perry, Dwight Dean, Clinical Associate in the Department of Ophthalmology
    • Prakalapakorn, Grace, Associate Professor of Ophthalmology
    • Richard, Michael Jason, Adjunct Assistant Professor in the Department of Ophthalmology
    • Sathiamoorthi, Saraniya, Clinical Associate in the Department of Ophthalmology
    • Scriven, Chelsea Anne, Medical Instructor in the Department of Ophthalmology
    • Seaber, Judy Herrington, Clinical Professor Emeritus of Ophthalmology
    • Shaw Jr., Harold Ellis, Consulting Associate in the Department of Ophthalmology
    • Skiba, Nikolai Petrovich, Associate Professor of Ophthalmology
    • Song, Chiyeon Diane, Assistant Consulting Professor in the Department of Ophthalmology
    • Su, Chien-Chia, Visiting Research Scholar in the Department of Ophthalmology
    • Sydnor, Charles Ford, Assistant Consulting Professor of Ophthalmology
    • Wang, Bo, Clinical Associate in the Department of Ophthalmology
    • Whitaker, Diane Beasley, Assistant Professor of Ophthalmology
    • White, Qiaohui Wei, Clinical Associate in the Department of Ophthalmology
    • Wiggins, Robert Earl, Consulting Associate in the Department of Ophthalmology
    • Wong, Fulton, Professor Emeritus in Ophthalmology
    • Wong, Tien Yin, Consulting Professor in the Department of Ophthalmology
    • Young, Terri Lois, Adjunct Professor in Ophthalmology
    • Youssif, Asmaa Ahmed Ali, Visiting Research Scholar in the Department of Ophthalmology

  • Secondary Appointments

    • Cummings, Thomas John, Professor of Ophthalmology
    • Izatt, Joseph A., Professor in Ophthalmology
    • Lobach, David Franklin, Associate Consulting Professor in the Department of Ophthalmology
    • Mac Grory, Brian C., Associate Professor in Ophthalmology
    • Proia, Alan David, Professor in Ophthalmology
    • Stinnett, Sandra Sue, Associate Professor in Ophthalmology
    • Whitson, Heather Elizabeth, Associate Professor in Ophthalmology
    • Yuan, Fan, Professor in Ophthalmology

  • Joint Appointments

    • Kay, Jeremy N., Associate Professor in Ophthalmology

  • Non-Faculty Positions

    • Abdelfattah, Nizar, House Staff
    • Adad Jammal, Alessandro, Research Scientist
    • Adetunji, Modupe, House Staff
    • Aggarwal, Sahil, House Staff
    • Cho, Juno, House Staff
    • Choi, Alice, House Staff
    • Donovan, Kelly, House Staff
    • Gabriel, Rami, House Staff
    • Gross, Andrew, House Staff
    • Hsu, Stephanie, House Staff
    • Hui, Lucy, House Staff
    • Konda, Sri Meghana, House Staff
    • Lee, Terry, House Staff
    • Li, Angela, House Staff
    • Lindeke-Myers, Aaron, House Staff
    • Liu, KeKe, House Staff
    • Malek, Davina, Research Scholar
    • McElroy, Gregory, House Staff
    • Morgan, Richard, House Staff
    • Peralta Chacon, Esteban, House Staff
    • Peters, Katherine, House Staff
    • Robbins, Cason, House Staff
    • Robbins, James, House Staff
    • Tian, James, House Staff
    • Woodward, Richmond, House Staff
    • Zheng, Yuxi, House Staff

  • Affiliate Positions

    • Naithani, Rizul, Affiliate
    • Song, Irene, Affiliate
• 

  Administers Grant

  • 018CTXX15001 An Obeservational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Populations Diagnosed with Early-Onset Idiopathic Bilateral Cataracts
  • 2016 Research to Prevent Blindness Unrestricted Grant
  • A 12-month study to investigate the efficacy, safety and pharmacokinetics of a monthly dosing regimen of ranibizumab (0.5 mg) in combination with pegpleranib (1.5mg), compared to monthly raranibizumab (0.5 mg) monotherapy, in patients with nAMD
  • A 12-month, multi-center, open-label study to investigate the safety of pegpleranib (1.5 mg) in combination with anti-VEGF agents, ranibizumab (0.5 mg) or aflibercept (2 mg), in Japanese patients with neovascular age-related macular degeneration
  • A 2-part study of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal EYE103 (Restoret®) in a mixed population of participants with DME and NVAMD
  • A 48 Week Phase II, Randomized, Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Two (2) EYS606 (pEYS606 administered by injection and electrotransfer to the ciliary muscle) Treatment Regimens in Patients with CNIU
  • A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration.
  • A CONTROLLED, MULTI-CENTER STUDY OF THE UTILIZATION AND SAFETY OF THE MK II INSERTER AND THE SAFETY OF THE FAI INSERT IN SUBJECTS WITH NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
  • A Deep Learning Model to Objectively Quantify Glaucomatous Damage on Fundus Photographs: Validation and Application to a Teleophthalmology Screening Program
  • A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
  • A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • A Multi-Center, Open-Label, Parallel-Arm, Randomized, Dose-Ranging Study of ENV515 (travoprost) Intracameral Implant in Subjects with Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma
  • A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment- Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD)
  • A PHASE 2/3 RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTIONS TO SUBJECTS WITH ACUTE NON ARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION)
  • A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE
  • A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH DIABETIC MACULA
  • A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 IN COMBINATION WITH RANIBIZUMB ADMINISTERED INTRAVITREALLY I
  • A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR¿CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (LUCERNE)
  • A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR¿CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)
  • A PHASE IIIb OPEN-LABEL, SINGLE-ARM STUDY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO EVALUATE THE USABILITY OF RANIBIZUMAB 10 mg/0.1 mL PREFILLED SYRINGE WITH THE PORT DELIVERY SYSTEM
  • A PHASE Ib STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH ADVANCED BRAFV600 WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI¿PD-1 THERAPY
  • A Ph3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety/Efficacy Study of a Fluocinolone Acetonide Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
  • A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies
  • A Phase 1/2 Dose-Escalation and Dose-Randomized, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration
  • A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Safety and Tolerability of Oral PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis
  • A Phase 1b, Prospective, Multicenter, Randomized, Single Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema (DME)
  • A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects with Severe Sepsis
  • A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to AMD
  • A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with nAMD
  • A Phase I Open-Label, Dose-Escalating, Multi-Center Trial to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration (AMD)
  • A Phase I/II, open-label, multicentre, dose escalation study assessing the safety and tolerability of pEYS606 when administered by electrotransfer (ET) in the ciliary muscle of patients with non infectious posterior, intermediate or panuveitis.
  • A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA) - FILLY
  • A Prospective Observational Study of Adult Strabismus
  • A RANDOMIZED TRIAL OF LOW-DOSE BEVACIZUMAB VERSUS LASER FOR TYPE 1 RETINOPATHY OF PREMATURITY (ROP3)
  • A RANDOMIZED, CONTROLLED, DOUBLE-MASKED, CROSSOVER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EXPLORATORY EFFICACY OF 1.0 mg LUMINATE® (ALG-1001) AS A TREATMENT FOR NON-EXUDATIVE MACULAR DEGENERATION
  • A Randomized Trial of Bilateral Lateral Rectus Recession versus Unilateral Lateral Rectus Recession with Medial Rectus Resection for Intermittent Exotropia
  • A Randomized Trial to Evaluate Sequential vs Simultaneous Spectacles plus Patching for Amblyopia in Children 3 to <13 Years Old (ATS22)
  • A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Diabetic Macular Edema
  • A Randomized, Double Masked, Active Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration
  • A Randomized, Parallel-Arm, Active Control, Multicenter Study Assessing the Safety and Efficacy of DEXTENZA® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
  • A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects with Behcet's Disease Uveitis
  • A non-canonical role for b-secretase in AMD
  • A novel animal model of normal-pressure glaucoma through genetic deletion of optineurin
  • A prospective, single-center, randomized, double masked, sham controlled study to evaluate the safety, efficacy and tolerability of OTX-TI (sustained release travoprost) Intracameral Depot compared to topical travoprost in subjects with OA & OHT.
  • A randomized, double-masked, active-controlled Phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration.
  • AERIE AR13324-CS301 (ROCKET 1)
  • AERIE AR13324-CS302 (MERCURY)
  • AN OBSERVATIONAL BILATERAL EVALUATION OF CORNEAL ENDOTHELIAL CELL DENSITY IN SUBJECTS WHO HAVE HAD A FLUOCINOLONE ACETONIDE IMPLANT FOR AT LEAST ONE YEAR
  • AR-13324-CS206
  • Acucela DRC A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects with Macular Atrophy Secondary to Stargardt Disease
  • Age-related autophagy function in an optineurin mouse model of normal-tension glaucoma
  • Aging and Vasculogenesis in Macular Degeneration
  • Alcon DRC OVID II RTH255-P001
  • Allgenesis DRC A Multicenter, Prospective, Randomized, Double-masked Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients with Pterygium
  • Alteration And Renovation
  • An Anatomical Analysis of the Supratrochlear Vessel and Considerations in Facial Filler Injections
  • An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Flucinolone Acetonide Intravitreal Implant
  • An RCT of Overminus Spectacle Therapy for Intermittent Exotropia
  • Ankyrin G in protein sorting between rod plasma membrane and photoreceptor discs
  • Applying OCT to visualize the retina and surgical instruments in eye surgery
  • Aquaporin 1 And Aqueous Humor Outflow In The Eye
  • Aquaporin And Aqueous Humor Outflow In The Human Eye
  • Astellas DRC Phase 1b, Dose Escalation Evaluation of Safety and Tolerability and a Ph 2, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to AMD
  • Autophagic Lysosomal Pathway and Glaucoma
  • Autophagy and Mechanotransduction in the Trabecular Meshwork
  • Bevacizumab Treatment for Posterior Zone I Retinopathy of Prematurity (ROP4)
  • Binocular Dig Rush Game Treatment for Amblyopia (ATS20)
  • Bone marrow neuropathy drives diabetic retinopathy
  • Brolucizumab Switch and Extend Ph IIIb Study: A Canadian, multi-center, single-arm, open label study assessing the efficacy and safety of brolucizumab 6mg in a Treat and Extend regimen in patients with nAMD with prior anti-VEGF exposure (PEREGRINE)
  • CATT OCT Reading Center
  • Cellular Senescence and Glaucoma
  • Cellular mechanism of targeting peripherin to the sensory cilium
  • Characterization of Genes in Normal and AMD Retinas
  • Characterizing and Comparing Surgical Management Options for Submacular Hemorrhage
  • Clinical Research Development Application
  • Comparison of AMD Treatment Trials-OCT Reading Center
  • Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial
  • Complement and Pathogenic Mechanisms of AMD
  • Conjunctival Goblet Cell Mucin Secretion in Inflammation and its Resolution
  • Coordinating Center for the Comparison of AMD Treatments Trials
  • Cryo-Rop Follow-Up Clinical Center
  • Cryo-Rop Participating Center
  • Cryo-Rop Participating Center - Phase Iii
  • Cryo-Rop Phase Iii
  • Cryo-Rop/Participating Center
  • Cytokine Modulation in Proliferative Vitreoretinopathy
  • DRC Editas Natural History Study of CEP290-Related Retinal Degeneration
  • Deprivation Effects On Central Auditory System Function
  • Developing a new therapeutic agent for retinal ciliopathies
  • Diabetic Retinopathy Clinical Research Network (DRCR.net)
  • Disruption of Mitochondria-related Vesicular Traffic by E50K Optineurin
  • Effects of rho kinase inhibitors on outflow facility and PEFL in human donor eyes
  • Effects of rho kinase inhibitors on outflow facility and PEFL in human donor eyes
  • Engineering Novel Bio-Inspired Materials for Stem Cell-Mediated Bone Regeneration
  • Evaluate Systemic Immunosuppression Regimens as Graft Rejection Prophylaxis Following Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to AMD
  • Evaluating a non-contact fundus camera for retinopathy of prematurity screening
  • Evaluation of anti-fibrotic response of AR-13324 in human trabecular meshwork primary culture model system
  • Evaluation of the Heidelberg Engineering SPECTRALIS with Flex Module for In-vivo Imaging in the Supine Position
  • Evaluation of the effects of topically administered IL-17 antagonist compound on ocular allergy parameters in the severe allergic eye disease (AED) mouse model
  • Examining the role of IFN-g+IL-17+ pathogenic Th17 cells in severe ocular allergy
  • Expanding Quality Care for Glaucoma through a Provider-Patient Partnership
  • Eye Problems in Concussed Children (EPICC) Study
  • Fiber Cell Cytoskeletal Scaffolds-Role in Lens Architecture and Function
  • Fiber Cell Membrane Organization-Role in Lens Architecture and Function
  • Flavoprotein Autofluorescence Imaging in AMD
  • GEMINI DRC Ph1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients with Geographic Atrophy (GA) Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103
  • GENENTECH DRC A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
  • GTS100-PAR: GLAUKOS ISTENT TRABECULAR MICRO-BYPASS STENT SYSTEM IN CONJUNCTION WITH CATARACT SURGERY POSTMARKET REGISTRY
  • Gemini DRC A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
  • Gemini DRC A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-central Geographic Atrophy (GA) Who Are Carriers of High-risk Genetic Variants of Complement Factor H (CFH)
  • Gemini DRC NH01 Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-central GA Who Are Carriers of High-risk Genetic Complement Variants Associated with Dry AMD
  • Gene and Protein Expression Profiling and Biomarkers in Experimental Glaucoma
  • Genentech -A PHASE III RANDOMIZED, VISUAL ASSESSOR MASKED, ACTIVE COMPARATOR, MULTICENTER EVALUATION OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH nAMD
  • Genentech DRC A MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY WITH OR WITHOUT DME
  • Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)
  • Genentech DRC A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
  • Genentech-A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A GENENTECH SPONSORED STUDY
  • Genetic Linkage Study - Macular Corneal Dystrophy
  • Genetic Studies of POAG in Ghana, West Africa
  • Genetic and Molecular Analyses of Protein Biogenesis in the Neuroretina
  • Genetic and Molecular Dissection of RanBP2-Mediated RanGTPase Functions
  • Genomic Convergence in Primary Open Angle Glaucoma
  • Genotype-Phenotype Correlations in Primary Congenital Glaucoma
  • Gertrude B. Elion Mentored Medical Research Award
  • Glaucoma Project Follow-up
  • Hemera DRC A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration with Geographic Atrophy
  • IONIS DRC A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to AMD
  • IVERIC DRC PH 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA¿ (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AMD
  • Icare Lending Library for Home IOP Monitoring in Pediatric Glaucoma
  • Icare Lending Library for Home IOP Monitoring in Pediatric Glaucoma Patients
  • Identification of unique rod outer segment plasma membrane proteins
  • Imaging to predict refractive outcomes after corneal endothelial keratoplasty
  • Immune Responses in Macular Degeneration
  • Immunohistochemistry (IHC) of Photothermal and Photomechanical Laser Lesions in the Retina to Support the BSELL Project
  • Improving Gaucoma Medication Adherence Through Education & Community Partnership
  • Improving the Quality of Diabetes Eye Care
  • In Silico Analysis of Ocular Genes and Proteins
  • In Vivo Modeling of Mitochondrial Complex I Deficiency in Retinal Ganglion Cells
  • Infant Aphakia Treatment Study (IATS)
  • Infant Aphakia Treatment Study (IATS)
  • Innovation Approaches to Gauge Progression of Sturge-Weber Syndrome
  • Instrumentation
  • Intermittent Exotropia Study (IXT6) A Pilot Randomized Clinical Trial of Base-in Prism Spectacles for Intermittent Exotropia
  • Kato DRC Safety and Treatment Benefit of RESOLV ER¿ in Subjects with Mild to Moderate Non-Proliferative Diabetic Retinopathy
  • LMRI DRC MacTel Phase II
  • LMRI DRC Phase 3 Clinical Trial of CNTF for MacTel Type 2-NTMT-03
  • Lipid Activated Nuclear Receptors in Age-Related Macular Degeneration
  • Lumithera DRC A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects with Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)
  • Lysosomal enzymes, Glycosaminoglycans and Outflow Pathway Physiology
  • Macrophages Drive Neovascular Remodeling in NVAMD
  • Macular Edema Treatment Trials Associated with MUST (META-MUST)
  • Mallinckrodt DRC A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate, Posterior, or Panuveitis
  • Masked, randomized, single-site, crossover study to determine the safety and tolerability of 2 concentrations of QLS-101 dosed for 14 days in adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure
  • Mechanisms Of Visual Transduction(Rcda)
  • Mechanisms in Exfoliation Glaucoma: Effect of Genetic Risk Variants and Ocular Cell Stressors on LOXL1 Expression
  • Mechanisms of RGC Loss in a Murine Model of Glaucoma
  • MicroRNA-directed modulation of intraocular pressure
  • Molecular Genetics of Inherited Eye Disease
  • Molecular Mechanisms of Corneal Recurrent Erosion Formation
  • Molecular Pathogenesis of Retinitis Pigmentosa Type 3
  • Molecular mechanisms of photoreceptor outer segment morphogenesis
  • Murine AMD Model Based on Constellation of Known Human AMD Risk Factors
  • NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center
  • NEI Clinical Vision Research Development Award
  • NEI Mentored Clinical Scientist Development Program Award (K12)
  • Negative regulation of NF-kB by optineurin in primary open angle glaucoma
  • Neuroinflammation: the role of lymphocytes in glaucoma
  • Neurotech DRC NT-503 (GEN 3)
  • Nonlinear Dynamical Characterization Neural Population Response Variability
  • Novartis DRC A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy
  • Novartis DRC A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg dosed Q4 weeks compared to Q8 weeks in high anti-VEGF-need patients with neovascular age-related macular degeneration (nAMD)
  • Novartis DRC A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macular degeneration (SWIFT)
  • Novartis DRC An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caused by mutations in the RLBP1 gene
  • Novartis DRC Basic human research study of novel glaucoma endpoints and identification of optimal patient populations for neuroprotection trials
  • Novartis DRC Brolucizumab post-marketing imaging project
  • Novartis DRC HAWK Centralized Imaging and Adjudication services, RTH258A/C1001502/I150 RTH258A2301
  • Novel Eye Dropper to Improve Adherence of Glaucoma Medicine Administration
  • Novel Retinal Biomarkers for Early Detection of Alzheimer's Disease
  • Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases
  • OCT measurement of TM/SC stiffness in living mice
  • OMEROS OMS302-ILR-007
  • ONL DRC A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients with Macula-off, Rhegmatogenous Retinal Detachment
  • Ocular Pharmacology and Therapeutics Conference
  • Ophthotech DRC Phase 2 OPH2007 - A Phase 2A Open-Label Trial to ASSESS the Safety of Zimura¿ (anti-c5) Administered in Combination With Lucentis® 0.5 mg in Treatment naive subjecTs with Neovascular Age related macular degeneration
  • Optic Neuritis Treatment Trial Cooperating Clinic
  • Optical Neuritis Treatment Trial Cooperating Clinic
  • Optimization of a Cell Culture Model for Pseudoexfoliation Syndrome
  • Oxidative Stress and Lysosomal Function in the Outflow Pathway
  • P30 - Center Core Grant for Vision Research: Administrative Supplement
  • PRN/Stealth DRC An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects with Intermediate Age-Related Macular Degeneration
  • Pathogenesis Of Retinal Ischemic Injury
  • Pathogenesis Of Retinal Ischemic Injury
  • Pediatric Cataract Surgery Outcomes Registry (CO2)
  • Pediatric Optic Neuritis Prospective Outcomes Study (PON1)
  • Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity (ROP1)
  • Photoceptor development in premature vs term infants
  • Photoreceptor Diseases Studied By Gene Transfer Methods
  • Pilot, open-label study of safety and tolerability of QLS-101 in adolescents with Sturge-Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP)
  • Portable Motion Compensated SDOCT System for Imaging Young Children
  • Prospective, Open-Label, Interventional, Single-Center Investigator- Initiated Trial of Combination ICG-Directed Visudyne (verteporfin) Photodynamic Therapy (PDT) and Intravitreal Lucentis (ranibizumab) for Trmt of patients with Neovascular AMD.
  • Protein Translocation and Photoreceptor Light Adaptation
  • Proteome Map of the Photoreceptor Cell
  • QLT DRC RET IRD 04: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)
  • ROCHE DRC PH 1 STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RO7250284 FOLLOWING ITV ADMINISTRATION OF UNMASKED MULTIPLE ASCENDING DOSES AND MASKED SUSTAINED DELIVERY FROM THE PORT DELIVERY SYSTEM IN PATIENTS WITH NAMD
  • RPB UNRESTRICTED GRANT (Calendar Year 2022)
  • RPB Unrestricted Grant - 2015
  • RPB: 2014 Nelson Trust Award
  • RPE Trophic Activity for Retinal Protection
  • RRF Merit Award
  • Randomized Trial of Full-Time Occlusion Therapy for Intermittent Exotropia in Children
  • Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
  • Rate of Progression in EYS-Related Retinal Degeneration (PRO-EYS)
  • Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)
  • Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F (RUSH1F)
  • Regenerative Capacity Of The Cornea
  • Regeneron DRC A Double Masked Randomized, Controlled Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema Regeneron VGFT-1009 - Extension
  • Regeneron DRC A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
  • Regenxbio DRC A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with RGX-314 in Subjects with Neovascular AMD (nAMD)
  • Regulation of Sub-RPE Deposit Formation in AMD by Local and Systemic Complement Factor H
  • Retinal Degeneration In Transgenic Pigs
  • Retinal Ganglion Cell Apoptosis in Experimental Glaucoma
  • Retinol, Lipofuscin & Autofluorescence in Dry Age-Related Macular Degeneration
  • Ripple DRC Ph 2 Evaluation of Safety and Efficacy of IBE-814 IVT Implant - A Sustained, Low Dose Dexamethasone Therapy for the Treatment of Patients with Diabetic Macular Edema (DMO) and Macular Edema due to Retinal Vein Occlusion (RVO).
  • River Vision RV001
  • River Vision DRC DME
  • Roche DRC Multi-center, non-randomized, open-label, multiple ascending dose study to investigate the safety, tolerability,pharmacokinetics, and pharmacodynamics of RO7200394 following intravitreal administration in patients with nAMD
  • Role of Exosomes in Glaucomatous Lamina Cribrosa Remodeling
  • Role of Rho Kinase in Aqueous Humor Outflow Pathway
  • Role of S100A4 in Lens Homeostasis and Function
  • Role of bona fide microglia in retinal degeneration
  • Role of impaired protein degradation in photoreceptor degeneration
  • Role of non-coding RNAs in glaucomatous outflow resistance dysregulation
  • SCD DRC A Phase 3 Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity between SCD411 and Eylea® in Subjects with Neovascular Age-related Macular Degeneration
  • STORE-OPERATED CALCIUM ENTRY IN RETINAL GANGLION CELLS
  • Same
  • Santen DRC AVANTE Study (Phase II) - Assess Efficacy, Safety of Intravitreal Injections of DE-122 in combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Wet AMD
  • SciFluor DRC Wet AMD study
  • Second Sight Argus II (PM-02-01)
  • Senju DRC A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients with Age-Related Macular Degeneration
  • Shear stress regulation of barrier function in Schlemm's canal
  • Smartphone Ophthalmoscope Lens Vascularity
  • Smartphone ophthalmoscope image analysis of lens capsule vascularity to estimate preterm gestational age
  • Structure-Function Analysis of RanBP2 in the Neuroretina
  • Studies Of Cochlear Efferent Function
  • Study of Genetic Basis of Fuchs Corneal Dystrophy
  • Subretinal Transplantation Of Islets Of Langerhans
  • Targeting Amyloid beta for the treatment of dry Age-related Macular Degeneration
  • Targeting Autotaxin for the treatment of glaucoma
  • Targeting the signaling pathway of a lipid activated nuclear receptor for the treatment of dry age-related macular degeneration.
  • Temporal dynamics of retinal ganglion cell neurodegeneration in glaucoma
  • Testing anti-S1P/LPA biologicals in living mice
  • The Molecular Basis of Pseudoexfoliation Syndrome
  • The Predictive Value of Pre-plus Disease inROP
  • The Retroject Device: A Novel Approach to Glaucoma Drug Delivery
  • The Role of Exosomes in Dry AMD
  • The role of a macrophage chemotactic factor in AMD
  • ThromboGenics DRC OASIS study - provide raw images
  • Thrombogenics DRC - A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-149 for the treatment of diabetic macular edema (DME)
  • Thrombogenics DRC A Phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of a single intravitreal injection of THR-687 for the treatment of diabetic macular edema (DME)
  • Trabecular Meshwork Cytoskeletal Signaling-Regulation of Aqueous Humor Outflow
  • Trabodenoson and conventional outflow function
  • Transduction Mechanisms Of Photoreceptors
  • Two-Year Follow Up after Treatment of Severe Retinopathy of Prematurity with Low-Dose Bevacizumab (ROP2Y)
  • UPENN - Additional Analysis of Data from the Comparison of Age-related Macular Degeneration Treatments Trials CATT and CATT Follow-up Study (CATT FS)
  • UPenn - NEI Follow-up Study: Comparison of AMD Treatment Trials (CATT) YR3
  • Understanding Photoreceptor Trafficking Pathways to the Outer Segment
  • Understanding the function of PRCD, a small protein whose mutations cause blindness
  • Unifying Genetics Epidemiology Of Macular Degeneration
  • Using Optical Coherence Tomography to Elucidate Optic Nerve Development in Healthy Infants and Children
  • Variability of Landmark Based Keratometry (VERION) Compared to Standard Automated Keratometry
  • Vascular Progenitor Cells in Neovascular AMD
  • Virtual Reality-based Pediatric Visual Field Testing for children with sightthreatening conditions
  • Vitrectomy And Proliferative Vitreoretinopathy
  • X-Ray Microanalysis And Image Processing System
  • pSivida PSV-FAI-001 Duke as Site
  • sGC stimulator effects on outflow facility
  • sGC stimulators and trabecular meshwork biology

• Sub-Organizations

Add data to my Website